GLP-1 medications and skin: why Ozempic, Wegovy and Mounjaro change how your skin sits

Quick answer

GLP-1 medications cause skin laxity not because of anything intrinsic to the drug class but because of how fast they drive weight loss. Skin elasticity does not keep pace with rapid fat loss the way it can with slow loss, particularly in patients over 35 or with a history of significant weight fluctuations. The result is the now-recognisable "Ozempic face" and its body-area cousins, deflation in the cheeks and temples, crepiness on the upper arms and thighs, redundant abdominal skin. None of this is permanent disfigurement; most of it is treatable with the right Australian protocol.

What is actually happening to your skin

Three things at once:

1. Subcutaneous fat is shrinking faster than the overlying skin can retract. Skin elasticity is driven by collagen and elastin in the dermis. Both proteins remodel slowly, months at the dermal level, often longer at the elastin level. Fat-pad volume can drop 30–50% in 12 months on a GLP-1 protocol; dermal protein synthesis cannot match that pace. [1]
2. Specific facial fat compartments are losing volume disproportionately. The face has discrete fat pads (deep medial cheek, malar, temporal, pre-jowl). These shrink at different rates with weight loss, producing the signature "drawn" or "deflated" look that is recognised as the post-GLP-1 face. [2]
3. Existing elastin damage from age, sun and weight fluctuation becomes visible. Elastin doesn't regenerate well in adult skin. If your dermis was already running on diminished elastin reserves before weight loss, the skin's recovery capacity is correspondingly limited.

This is not unique to GLP-1 medications: the same pattern is described after bariatric surgery, after rapid post-pregnancy loss, after intensive caloric-restriction programs. What's different about the GLP-1 era is the scale (Australian GLP-1 sales rose roughly 10× between May 2020 and April 2025 [3]) and the predictability of the loss profile: semaglutide and tirzepatide consistently produce 12–22% body-weight reduction over 12 months in the published trials, [4] faster than the slow-loss programs the older dermatology literature was built on.

Who tends to get this worse, and who tends to get away with it

Worse outcomes are statistically more common in:

• People over 40, collagen and elastin synthesis already running at a lower baseline
• Significant total weight loss (25 kg+)
• Loss in 6–12 months rather than 18–36 months
• A history of significant weight fluctuations
• Sun-damaged baseline skin
• Smokers and recent ex-smokers
• Those with a thinner dermis genetically (often paler-skinned)

Better outcomes are more common in:

• Younger patients (under 35)
• Smaller total losses (10–15 kg)
• Slow loss (1 kg per month or less)
• A history of resistance training during weight loss (preserves muscle tone, which improves the silhouette even when skin lags)
• Excellent baseline skin care, particularly long-term retinoid use
• People who started on GLP-1 within a year of pregnancy or another physiological recovery state

You don't get to choose most of these. But you do get to choose your rate of loss, your resistance training, your topical skin program, and when you start an in-clinic protocol. Those four levers do most of the work.

What the timeline looks like

A realistic post-GLP-1 timeline in Australia:

• Months 0–6 of GLP-1 use: the priority is the GLP-1 protocol itself, side-effect management, and resistance training. Skin care is supportive: sunscreen, retinoid, hydration. Don't start in-clinic skin protocols yet.
• Months 6–12: most patients have lost the bulk of what they will lose. Skin laxity may already be visible. Continue the topical program. Avoid making aesthetic decisions on a face that is still actively changing.
• Months 12–15: weight loss often begins to plateau or stabilises on a maintenance dose. This is the right time to start an in-clinic skin assessment.
• Months 15–24: once weight has been stable for at least 3 months, an Australian protocol typically combines RF microneedling, bio-stimulators, HIFU or surface RF for facial lift, and a continuing topical program over 6–12 months.
• Months 24+: for patients with true skin redundancy that didn't resolve with non-surgical work, a consultation with a specialist plastic surgeon (FRACS) for body-contouring options is reasonable.

The single biggest planning mistake is starting in-clinic protocols too early, before weight has stabilised, and watching the result get partially undone by ongoing loss.

What it costs (in time and money)

A "default" mid-range Australian post-GLP-1 skin program over 12 months looks roughly like:

• Daily topical program: $1,000–$3,000 per year
• RF microneedling, 3 sessions: $3,000–$8,000
• Bio-stimulator program (Sculptra, Profhilo or hyperdiluted Radiesse): $2,800–$6,000
• HIFU or Ultherapy, single session: $1,500–$4,500
• Optional dermal filler for facial volume: $2,800–$6,000

Total non-surgical mid-range: $11,000–$27,500 over 12 months.

Lower-budget programs that prioritise topicals + a single in-clinic modality come in well under that. Higher-budget programs that add fractional laser, multiple bio-stimulator courses, or a surgical capstone go well above. There is no "right" budget, the right plan is the one that's calibrated to your actual laxity pattern and what you actually have to spend.

If body-contouring surgery is part of the plan, that is a separate $15,000–$60,000+ program layered over the non-surgical work, usually starting at the 18–24 month mark.

What can go wrong if you don't address it

The most common patterns:

• Stalling at "good enough" weight loss to avoid worse skin: choosing to stay 5–10 kg above your target weight because every additional kilo lost looks like additional laxity. This is a real pattern and a worse health outcome than dealing with the skin, given that obesity is itself a chronic disease that warrants active management. [5]
• Stopping GLP-1 before stabilisation, then regaining: the worst possible cycle for skin, because each loop worsens elastin damage.
• Booking aggressive in-clinic procedures during active weight loss: money mostly wasted because the skin keeps changing.
• Believing online "Ozempic face fixer" content: most of the popular content is US-coded and doesn't translate to Australian pricing or practitioners.
• Avoiding the surgical conversation when surgery is the right answer, true skin redundancy will not respond to energy-based devices, and pretending otherwise is expensive.

A planning conversation with a clinician who knows the post-weight-loss patient profile, and who is willing to recommend "do nothing yet" when that's the right call, is the single highest-leverage thing you can do.

How to plan a sensible response

A practical framework:

1. Stabilise first. Don't start in-clinic skin protocols until you've been weight-stable for at least 3 months on a maintenance dose.
2. Build the topical program now. Start retinoid + ceramide + SPF + (optional) copper peptides as soon as you're on a GLP-1, not at the end. The compounding effect over 12+ months is real.
3. Assess with a senior clinician. Look for an AHPRA-registered cosmetic physician, dermatologist, or specialist plastic surgeon (FRACS) who explicitly works with post-major-weight-loss patients. The pattern recognition is different from a regular ageing consultation.
4. Layer rather than stack. A program of one in-clinic modality at a time, with adequate recovery between, almost always outperforms doing everything at once.
5. Reserve surgery for true redundancy. If non-surgical work is clearly insufficient by month 18, the conversation with a specialist plastic surgeon (FRACS) is the right next step.
6. Know that some of this is going to settle on its own. A measurable amount of skin retraction happens over 12–18 months post-stabilisation without any treatment. Don't blow your budget at month 4.

This is editorial information, not medical advice. Talk to your treating clinician about your specific case.

Frequently asked questions

Is 'Ozempic face' a real medical term?

Can I prevent skin laxity by losing weight more slowly?

Will my skin go back to normal if I stop the GLP-1 and regain weight?

Do I need to stop my GLP-1 to do skin treatments?

Is there a future GLP-1 protocol that doesn't cause skin laxity?

Continue

Browse all treatmentsGet the free guide

Sources cited

1. Baillot A et al. What is known about the correlates and impact of excess skin after bariatric surgery: a scoping review. Obesity Surgery, 2017.
2. Rohrich RJ, Pessa JE. The fat compartments of the face: anatomy and clinical implications for cosmetic surgery. Plastic and Reconstructive Surgery, 2007.
3. Falster MO et al. The GLP-1 RA boom: trends in publicly subsidised and private access in Australia, 2020–2025. UNSW Medicines Intelligence Research Program, medRxiv preprint, 2025.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021.
5. Royal Australian College of General Practitioners (RACGP). Obesity prevention and management (position statement), 2025.
6. Kitzinger HB et al. After massive weight loss: patients' expectations of body contouring surgery. Obesity Surgery, 2012.

Written by

Dan d'Auvergne-Massie· Founder & CEO, HALO

Lost 36kg on a GLP-1 protocol and spent the next two years researching what actually tightens skin after rapid weight loss. Works professionally in the peptide industry. Not a doctor: every clinical claim on this site is sourced.

Last reviewed: 1 May 2026